---
title: Comparison of the Ankle-Brachial Index Measurement Using a Specific Oscillometric Device vs. the Doppler Method
nct_id: NCT03511612
overall_status: COMPLETED
phase: NA
sponsor: University Hospital, Limoges
study_type: INTERVENTIONAL
primary_condition: Peripheral Arterial Disease, Ankle Brachial Index, Doppler
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03511612.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03511612"
ct_last_update_post_date: 2025-08-01
last_seen_at: "2026-05-12T06:29:41.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Comparison of the Ankle-Brachial Index Measurement Using a Specific Oscillometric Device vs. the Doppler Method

**NCT ID:** [NCT03511612](https://clinicaltrials.gov/study/NCT03511612)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 51
- **Lead Sponsor:** University Hospital, Limoges
- **Conditions:** Peripheral Arterial Disease, Ankle Brachial Index, Doppler
- **Start Date:** 2018-04-24
- **Completion Date:** 2018-10-24
- **CT.gov Last Update:** 2025-08-01

## Brief Summary

Several methods are available to measure ankle brachial index (ABI) non-invasively. A recent scientific statement of the AHA considers the Doppler method as the reference. However because Doppler devices are not widely available in primary care, several attempts have been made to propose alternative methods, among whom oscillometric methods (automatic blood pressure machines) have attracted most attention.

We hypothesize that:

\- the diagnostic characteristics (i.e. sensitivity, specificity and AUC) of the oscillometric method would be very good as compared to the Doppler method.

the oscillometric method would have better intra- and inter-observer reproducibilities as compared to the Doppler method.

## Eligibility

- **Minimum age:** 60 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

Patients referred with the suspicion of PAD, either because of:

* symptoms in favor of intermittent claudication or more atypical pain when walking, or
* asymptomatic individuals with the presence of at least 2 cardiovascular risk factors among the following :

  * Men \> 60 years or women \> 65 years
  * Regular cigarette smoking \>10 years, either current or in the past
  * Treated Type-2 diabetes \>5 years or Type-1 diabetes \>20 years
  * Treated hypertension
  * High blood cholesterol (either total-C \>240 mg/dl or LDL-C \>160 mg/dl) or treated by statins or other lipid-lowering agents
  * Documented history of coronary artery disease (history of PCI or CABG, or previous myocardial infarction, or CAD documented by coronary angiography)
  * Documented history of ischemic stroke

Exclusion Criteria:

* Patients with revascularized PAD
* Patients with critical limb ischemia or leg/foot ulcers
* Cardiac arrhythmia: Atrial fibrillation, atrial flutter, frequent supra- and ventricular ectopic beats
* Patients under dialysis
```

## Arms

- **Pattern A** (OTHER) — Intervention : Each subject has 3 measurements of ABI starting with oscillometric device and then using the Doppler method.
- **Pattern B** (OTHER) — Intervention : Each subject has 3 measurements of ABI starting with Doppler method and then using oscillometric device.

## Interventions

- **Measure ankle brachial index (ABI)** (DIAGNOSTIC_TEST) — This is a head-to-head comparison of 2 methods of determination of the ABI, taking the Doppler method as the standard and the oscillometric device AVP as the challenger

## Primary Outcomes

- **Measurement of the ABI** _(time frame: Day of the inclusion)_ — Measurement of the ABI, with Doppler method as reference

## Locations (1)

- University Hospital, Limoges, France

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university hospital|limoges||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03511612.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03511612*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*